SK280005B6 - Použitie lignanových derivátov - Google Patents

Použitie lignanových derivátov Download PDF

Info

Publication number: SK280005B6
Authority: SK; Slovakia
Prior art keywords: glucopyranoside; amyloid; amyloidosis; treatment; podophyllotoxin
Prior art date: 1993-05-28

Application number

SK1464-95A

Other languages

English (en)

Slovak (sk)

Other versions

SK146495A3 (en

Inventor

B�Rje Ros�N

Kurt Leander

Original Assignee

Conpharm Ab

Analytecon Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-28

Filing date

1994-05-25

Publication date

1999-07-12

1994-05-25 Application filed by Conpharm Ab, Analytecon Sa filed Critical Conpharm Ab

1996-06-05 Publication of SK146495A3 publication Critical patent/SK146495A3/sk

1999-07-12 Publication of SK280005B6 publication Critical patent/SK280005B6/sk

Links

229930013686 lignan Natural products 0.000 title claims description 7
150000005692 lignans Chemical class 0.000 title claims description 7
235000009408 lignans Nutrition 0.000 title claims description 7
238000011282 treatment Methods 0.000 claims abstract description 17
206010002022 amyloidosis Diseases 0.000 claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 7
238000011321 prophylaxis Methods 0.000 claims abstract description 6
208000020016 psychiatric disease Diseases 0.000 claims description 6
208000023769 AA amyloidosis Diseases 0.000 claims description 3
206010039811 Secondary amyloidosis Diseases 0.000 claims description 3
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 1
150000001241 acetals Chemical class 0.000 abstract description 5
125000000217 alkyl group Chemical group 0.000 abstract description 3
125000003118 aryl group Chemical group 0.000 abstract description 3
125000000623 heterocyclic group Chemical group 0.000 abstract description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
230000000694 effects Effects 0.000 description 15
239000000203 mixture Substances 0.000 description 14
150000001875 compounds Chemical class 0.000 description 13
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
208000024827 Alzheimer disease Diseases 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
239000000126 substance Substances 0.000 description 7
102000001049 Amyloid Human genes 0.000 description 6
108010094108 Amyloid Proteins 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
206010039073 rheumatoid arthritis Diseases 0.000 description 5
229940109239 creatinine Drugs 0.000 description 4
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 4
YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
208000005314 Multi-Infarct Dementia Diseases 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
208000025966 Neurological disease Diseases 0.000 description 3
206010039966 Senile dementia Diseases 0.000 description 3
201000004810 Vascular dementia Diseases 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 3
229960001237 podophyllotoxin Drugs 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
206010002023 Amyloidoses Diseases 0.000 description 2
208000027932 Collagen disease Diseases 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000031864 metaphase Effects 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
239000003600 podophyllotoxin derivative Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
101710105825 Protein vein Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
230000018199 S phase Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
230000003941 amyloidogenesis Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229930003944 flavone Natural products 0.000 description 1
150000002213 flavones Chemical class 0.000 description 1
235000011949 flavones Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000028993 immune response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
231100000707 mutagenic chemical Toxicity 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
-1 podophyllotoxin glycosides Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
208000022256 primary systemic amyloidosis Diseases 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
208000027121 wild type ATTR amyloidosis Diseases 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

SK1464-95A 1993-05-28 1994-05-25 Použitie lignanových derivátov SK280005B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE19939301831A SE9301831D0 (sv)	1993-05-28	1993-05-28	Pharmaceutical compositions
PCT/SE1994/000493 WO1994027614A1 (en)	1993-05-28	1994-05-25	Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis

Publications (2)

Publication Number	Publication Date
SK146495A3 SK146495A3 (en)	1996-06-05
SK280005B6 true SK280005B6 (sk)	1999-07-12

Family

ID=20390089

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1464-95A SK280005B6 (sk)	1993-05-28	1994-05-25	Použitie lignanových derivátov

Country Status (15)

Country	Link
US (1)	US5637571A (sv)
EP (1)	EP0700296A1 (sv)
JP (1)	JPH09505270A (sv)
CN (1)	CN1126947A (sv)
AU (1)	AU694431B2 (sv)
BR (1)	BR9406655A (sv)
CA (1)	CA2163887A1 (sv)
CZ (1)	CZ285590B6 (sv)
HU (1)	HUT73812A (sv)
NO (1)	NO308883B1 (sv)
RU (1)	RU2148407C1 (sv)
SE (1)	SE9301831D0 (sv)
SK (1)	SK280005B6 (sv)
UA (1)	UA41367C2 (sv)
WO (1)	WO1994027614A1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4677496A (en) *	1995-02-21	1996-09-11	Takeda Chemical Industries Ltd.	Use of helioxanthin as an enhancer of cell differentiation inducing factors
WO1997026919A2 (en) *	1996-01-24	1997-07-31	Warner-Lambert Company	Method of imaging amyloid deposits
KR100416120B1 (ko) *	1997-11-15	2004-05-07	동화약품공업주식회사	천연물로부터 분리한 신규 리그난계통의 항종양 물질
CU20130027A7 (es)	2013-02-28	2014-10-30	Ct De Neurociencias De Cuba	Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB823068A (en) *	1955-05-13	1959-11-04	Sandoz Ltd	Condensation products from glucosides
DE3584370D1 (de) *	1984-12-28	1991-11-14	Conpharm Ab	Verwendung von podophyllotoxin und dessen derivaten.

1993
- 1993-05-28 SE SE19939301831A patent/SE9301831D0/sv unknown
1994
- 1994-05-25 EP EP94917855A patent/EP0700296A1/en not_active Withdrawn
- 1994-05-25 BR BR9406655A patent/BR9406655A/pt not_active Application Discontinuation
- 1994-05-25 JP JP7500542A patent/JPH09505270A/ja not_active Ceased
- 1994-05-25 AU AU69398/94A patent/AU694431B2/en not_active Ceased
- 1994-05-25 SK SK1464-95A patent/SK280005B6/sk unknown
- 1994-05-25 US US08/553,423 patent/US5637571A/en not_active Expired - Fee Related
- 1994-05-25 CZ CZ953106A patent/CZ285590B6/cs not_active IP Right Cessation
- 1994-05-25 CA CA002163887A patent/CA2163887A1/en not_active Abandoned
- 1994-05-25 RU RU95122727A patent/RU2148407C1/ru active
- 1994-05-25 HU HU9503351A patent/HUT73812A/hu unknown
- 1994-05-25 WO PCT/SE1994/000493 patent/WO1994027614A1/en not_active Application Discontinuation
- 1994-05-25 UA UA95125474A patent/UA41367C2/uk unknown
- 1994-05-25 CN CN94192741A patent/CN1126947A/zh active Pending
1995
- 1995-11-27 NO NO954806A patent/NO308883B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0700296A1 (en)	1996-03-13
HUT73812A (en)	1996-09-30
NO954806D0 (no)	1995-11-27
AU6939894A (en)	1994-12-20
JPH09505270A (ja)	1997-05-27
SK146495A3 (en)	1996-06-05
AU694431B2 (en)	1998-07-23
NO308883B1 (no)	2000-11-13
UA41367C2 (uk)	2001-09-17
BR9406655A (pt)	1996-03-19
CA2163887A1 (en)	1994-12-08
CZ285590B6 (cs)	1999-09-15
WO1994027614A1 (en)	1994-12-08
HU9503351D0 (en)	1996-01-29
SE9301831D0 (sv)	1993-05-28
CN1126947A (zh)	1996-07-17
CZ310695A3 (en)	1996-04-17
NO954806L (no)	1996-01-26
US5637571A (en)	1997-06-10
RU2148407C1 (ru)	2000-05-10

Publication	Publication Date	Title
RU2170738C2 (ru)	2001-07-20	Замещенные липосахариды, используемые для лечения и профилактики эндотоксикоза
CA2104196C (en)	2001-03-27	Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
KR0165131B1 (ko)	1999-02-18	1,4-벤조티아제핀 유도체
RU2501792C2 (ru)	2013-12-20	Соединения, композиции и способы, предназначенные для лечения бета-амилоидных заболеваний и синуклеинопатий
US20040014806A1 (en)	2004-01-22	Methods and compositions for lowering levels of blood lipids
EP2459544A2 (en)	2012-06-06	Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
KR20110044947A (ko)	2011-05-03	과잉활성 면역계 치료를 위한 사이클로리그난의 용도
RU2268727C2 (ru)	2006-01-27	Лекарственное средство, обладающее защитным действием в отношении окислительно-токсических и прежде всего кардиотоксических соединений
EP1972338A1 (en)	2008-09-24	Anti-infective agents
SK280005B6 (sk)	1999-07-12	Použitie lignanových derivátov
US5455268A (en)	1995-10-03	Esculetin derivatives and pharmaceutical composition
WO2022146914A1 (en)	2022-07-07	Cromolyn derivatives and uses thereof
AU690814B2 (en)	1998-04-30	Method for treating multiple sclerosis
TWI695839B (zh)	2020-06-11	雙（羥甲基）吡咯并酞嗪混成物、其之製備方法與用途
US7067528B2 (en)	2006-06-27	1, 2-dihydro-2-oxo-1, 8-naphthyridine derivative
US4737521A (en)	1988-04-12	Suramin sodium for use as an immunostimulant
CZ321095A3 (en)	1996-09-11	Heterocyclic compounds
JPH0154326B2 (sv)	1989-11-17
PT93009A (pt)	1990-07-31	Processo para a preparacao de novos acidos aril- ou heteroaril-1-alquil-pirrol--2-carboxilicos uteis no tratamento de situacoes mediadas pela interleucina -1
WO1994006762A1 (en)	1994-03-31	Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
TW387893B (en)	2000-04-21	A pharmaceutical composition for the treatment or prophylaxis of states of secondary amyloidosis
KR19990044231A (ko)	1999-06-25	6-엔-(엘-에이엘에이-엘-에이엘에이)-트로바플록사신 전구약물의 폴리모프
US3502687A (en)	1970-03-24	Dioxinopiperidines
JPS6368591A (ja)	1988-03-28	光学活性なジヒドロピリジン−５−ホスホン酸エステル
JPH0673027A (ja)	1994-03-15	癌化学療法補助剤